Description: Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Home Page: www.oncopeptides.com/sv
Vastra Tradgardsgatan 15
Stockholm,
111 53
Sweden
Phone:
46 86 15 20 40
Officers
| Name | Title |
|---|---|
| Dr. Jakob Lindberg Med. Lic | Chief Exec. Officer |
| Prof. Rolf Larsson M.D., Ph.D. | Founder |
| Prof. Rolf Lewensohn M.D., Ph.D. | Founder |
| Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. | Founder |
| Dr. Kristina Luthman Ph.D. | Founder |
| Prof. Hans Ehrsson M.D. | Founder |
| Mr. Peter Nygren | Founder |
| Ms. Annika Muskantor M.B.A. | Interim Chief Financial Officer |
| Ms. Eva Nordström M.Sc., MSc Pharm | COO & Deputy MD |
| Ms. Linda Holmstrom | Director of Investor Relations |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9564 |
| Price-to-Sales TTM: | 34.7582 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |